Novo Nordisk バランスシートの健全性 Novo Nordiskの総株主資本はDKK120.5B 、総負債はDKK57.0Bで、負債比率は47.3%となります。総資産と総負債はそれぞれDKK397.4BとDKK276.9Bです。 Novo Nordiskの EBIT はDKK119.8Bで、利息カバレッジ比率-262.7です。現金および短期投資はDKK74.9Bです。
主要情報 インタレスト・カバレッジ・レシオ -262.7x 現金 DKK 74.88b エクイティ DKK 120.52b 負債合計 DKK 276.92b 総資産 DKK 397.44b
財務の健全性に関する最新情報
すべての更新を表示 Novo Nordisk A/S to Report Q2, 2025 Results on Aug 06, 2025
Novo Nordisk A/S Provides Earnings Guidance for 2024 Nov 07
Novo Nordisk A/S Announces Results from Part 1 of the Ongoing ESSence Trial Nov 02 Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed Sep 20
Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake Sep 18 Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events Jul 26
Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec Jul 11 Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada Mankind Reportedly Joins Race for Healthium Medtech Mar 30
Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion. Mar 25
Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities Mar 23
Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events Novo Nordisk A/S Proposes Final Dividend for the Year 2023 Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares. Jan 31
Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema Jan 09
Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024
Novo Nordisk Revises Earnings Guidance for the Year 2023 Oct 14 Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis Oct 11
Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million. Aug 31 Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion. Aug 11
Novo Nordisk A/S Provides Earnings Guidance for the Year 2023 Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million. Jun 20
Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares Jun 05
Novo Nordisk A/S Announces Headline Results from OASIS 1 May 23 Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024 May 05
財務状況分析
短期負債: 0TDDの 短期資産 ( DKK195.2B ) は 短期負債 ( DKK208.4B ) をカバーしていません。
長期負債: 0TDDの短期資産 ( DKK195.2B ) が 長期負債 ( DKK68.6B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: 0TDD総負債よりも多くの現金を保有しています。
負債の削減: 0TDDの負債対資本比率は、過去 5 年間で8.2%から47.3%に増加しました。
債務返済能力: 0TDDの負債は 営業キャッシュフロー によって 十分にカバー されています ( 207.5% )。
インタレストカバレッジ: 0TDD支払う利息よりも稼ぐ利息の方が多いので、 利息支払い の補償は問題になりません。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.